(Q54593894)

1 June 2018

title

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. (English)

1 reference

1 June 2018

1 reference

1 reference

5

1 reference

1 June 2018

author name string

J Kirchheiner

1

1 reference

1 June 2018

H Schmidt

2

1 reference

1 June 2018

M Tzvetkov

3

1 reference

1 June 2018

J-T H A Keulen

4

1 reference

1 June 2018

I Roots

6

1 reference

1 June 2018

J Brockmöller

7

1 reference

1 June 2018

publication date

4 July 2006

1 reference

1 June 2018

The Pharmacogenomics Journal

published in

1 reference

1 June 2018

volume

7

1 reference

1 June 2018

issue

4

1 reference

1 June 2018

page(s)

257-265

1 reference

1 June 2018

Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Molecular diversity at the CYP2D6 locus in the Mediterranean region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

CYP2D6 genotyping by a multiplex primer extension reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Opioid receptor and peptide gene polymorphisms: potential implications for addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

A genetic association study of the mu opioid receptor and severe opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

The role of active metabolites in dihydrocodeine effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500406

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500406

1 reference

1 June 2018

1 reference

1 June 2018